Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)



Status:Terminated
Conditions:Diabetic Neuropathy
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - Any
Updated:2/11/2017
Start Date:May 2014
End Date:February 8, 2017

Use our guide to learn which trials are right for you!

A Double-Blind, Placebo-Controlled, Randomized, Parallel Assignment, U.S. Study of Ranolazine for the Treatment of Patients With Diabetic Peripheral Neuropathic Pain (DPNP)

The purpose of this trial is to determine if patients suffering from diabetic peripheral
neuropathic pain treated with ranolazine will have a greater reduction in pain compared to
placebo.

Hypothesis: From the prior clinical observations, and analgesic efficacy in the preclinical
animal model of neuropathic pain, the investigators hypothesize that subjects randomized to
ranolazine will show a greater reduction in diabetic neuropathic pain compared to placebo.


Inclusion Criteria:

1. A minimum of 18 years of age;

2. Provided signed Informed Consent Form and Health Insurance Portability and
Accountability Act (HIPAA) authorization for this study approved by the Institutional
Review Board;

3. Patients must have diabetic peripheral neuropathic pain rated at an average level of
six (6) or above as documented in daily diary prior to baseline visit and noted at
Baseline Visit;

4. Diabetic on a stable insulin regimen or oral medication regimen as determined by the
investigator [It is recommended Hba1c < 9.5%, making a note that lab normal values
may vary among sites.];

5. Clinical Exam Results:

1. 5.07 Semmes-Weinstein Monofilament Test Subject does not sense monofilament or
evokes an abnormal response in a minimum of two (2) out of five (5) test
locations on the plantar surface of the foot.

2. Pin Prick Test Subject experiences allodynia, hyperalgesia, or sensory loss in
two (2) out of five (5) test locations in the plantar surface - four (4) and
dorsum - one (1) of the foot.

6. Willing and able to comply with the requirements of the protocol and follow
directions from the clinic and research staff;

7. For female patients only:

- Be post-menopausal (no menses for at least 2 years) or sterilized,

- If subject of childbearing potential, not breastfeeding, has a negative
pregnancy test at Baseline (pre-randomization, Day 0), has no intention of
becoming pregnant during the course of the study, and is using one or more of
the following contraceptive measures:

1. Stable regimen of hormonal contraception

2. Intra-uterine device

3. Condoms with spermicide

4. Diaphragm with spermicide

Exclusion Criteria:

1. History of allergy or intolerance to ranolazine;

2. Any condition or concomitant medication that would preclude the safe use of
ranolazine as outlined in the prescribing information sheet;

3. In the judgment of the investigator, any clinically-significant ongoing medical
condition that might jeopardize the patient's safety or interfere with the
absorption, distribution, metabolism or excretion of the study drug;

4. In the judgment of the investigator, clinically-significant abnormal physical
findings during screening (excluding the patient's peripheral neuropathy condition);

5. Use participation in another experimental or investigational drug or device trial;

6. Pregnant or breast feeding;

7. Cirrhosis of the liver;

8. Psychological or addictive disorders (not limited to, but including for example, drug
and/or alcohol dependency) that may preclude patient consent or compliance, or that
may confound study interpretation;

9. Taking a moderate or strong CYP3A inhibitor (e.g. diltiazem, verapamil, ketoconazole,
itraconazole, clarithromycin, erythromycin, nefazodone, nelfinavir, ritonavir,
indinavir, and saquinavir);

10. Taking inducers of Cytochrome P450, family 3, subfamily A (CYP3A) (e.g. rifampin,
rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John's
wort);

11. Renal impairment as defined by a calculated serum creatinine clearance of < 30ml/min;

12. Lower back disorders where symptoms present similarly to DPNP;

13. Family history of long QT syndrome;

14. Congenital long QT syndrome;

15. Subjects taking tricyclic antidepressants;

16. Subjects taking anti-psychotic drugs;

17. Patient is taking > 850mg metformin BID;

18. Any subjects currently taking pregabalin;

19. Any subjects currently taking gabapentin;

20. Any subject currently taking Metanx®;

21. Any subjects currently taking continuous long-term narcotics;

22. Grapefruit and grapefruit containing products;

23. Use of P-gp inhibitors - cyclosporine.
We found this trial at
3
sites
Houma, Louisiana 70360
Principal Investigator: Craig M Walker, MD FACC
Phone: 985-873-5613
?
mi
from
Houma, LA
Click here to add this to my saved trials
Fairhope, Alabama 36532
Principal Investigator: Frank T Bunch, MD FACC
Phone: 251-990-1936
?
mi
from
Fairhope, AL
Click here to add this to my saved trials
Lafayette, Louisiana 70506
Principal Investigator: Nick Cavros, MD FACC
Phone: 337-289-8429
?
mi
from
Lafayette, LA
Click here to add this to my saved trials